entrinsic bioscience

Executive Summary

Entrinsic Bioscience is a private biotechnology company that leverages a proprietary biomapping and electrophysiology platform to discover and develop functional amino acid combinations. Founded in 2009 and headquartered in Norwalk, CT, the company targets metabolic and gastroenterology health sectors, creating ingredients and APIs designed to modulate protein regulation and cell signaling. Its patented platform enables the development of clinically proven, plant-based products for applications in pulmonary, digestive, immune, metabolic, hydration, and skin health. By focusing on the intersection of amino acid science and electrophysiology, Entrinsic aims to address unmet needs in gut health and metabolic disorders with novel, natural-derived therapeutics. The company's technology has the potential to disrupt the functional ingredients market by offering scientifically validated, plant-based alternatives to synthetic compounds. While Entrinsic has not disclosed significant funding rounds or valuation, its focus on high-growth areas like metabolic health and gastroenterology positions it well for partnerships with pharmaceutical and consumer health companies. The lack of publicly available clinical pipelines suggests the company is still in early development stages, but its platform's versatility across multiple health indications offers a broad range of opportunities. Key risks include the long timeline to clinical validation and competitive pressure from established biotech firms.

Upcoming Catalysts (preview)

• H2 2026Announcement of Lead Candidate Entering Clinical Trials40% success
• 2026Strategic Partnership with a Major Consumer Health Company30% success
• TBDPublication of Clinical Data for Gastrointestinal Health Product25% success